HEYGOOD, ORR, REYES, PEARSON & BARTOLOMEI
2331 W. Northwest Hwy., 2nd Floor • Dallas, TX 75220 • Phone: 214.526.7900 • Fax: 214.526.7910 • Toll-Free: 877.308.7900
Rezulin
Rezulin, (generically known as Troglitazone), is a prescription-only drug manufactured by Parke-Davis Pharmaceuticals, a division
of Warner-Lambert. It was approved by the FDA and marketed
for sale in January, 1997 to treat Type 2 (adult-onset) diabetes.
While on the market, Rezulin generated over $1.8 billion in
sales. Rezulin was beneficial for Type 2 diabetics in that it helped regulate blood glucose levels that could not be controlled by other forms of therapy. However, it quickly became clear that Rezulin's severe side effects far outweighed its benefits.
Just eight months after Rezulin was introduced into the market, numerous reports of liver failure were received by the FDA. The FDA then ordered the manufacturer to use stronger warning labels. Letters were also written to doctors that instructed them to perform liver enzyme tests to measure liver toxicity. Four changes were made to warning labels, and four letters were sent to doctors before Rezulin was finally withdrawn from the market in March, 2000. Upon its withdrawal, 94 reports of liver failure had been linked to Rezulin, with 63 reported liver poisoning deaths.
If you or someone you care about has been taking Rezulin and experienced any liver problems, please fill out our Case Review Contact Form to the right on this page to find out what your case is worth.
NEWS ARTICLES
Panel May Issue Subpoenas Related to FDA Approval
on Antibiotic Drug Ketek
1/28/08 - FDA
The House Energy and Commerce Oversight and Investigations Subcommittee will
vote Tuesday on subpoenaing Food and Drug Administration criminal
investigators and documents related to a potentially deadly drug the FDA
approved despite receiving fabricated data, according to a subcommittee memo
obtained by CongressDaily. (read more..)
Second Safety Warning on Fentanyl Skin Patch
12/21/07 - FDA
FDA issued its second safety warning on Dec. 21, 2007, about the fentanyl transdermal system, an adhesive patch that delivers a potent pain medicine through the skin. (read more..)
F.D.A. Investigates Quit-Smoking Drug
11/20/07 - Associated Press
New York Times (AP)
Government scientists are investigating whether a drug from Pfizer used to help
smokers quit cigarettes also increases suicidal thoughts and violent behavior. (read
more..)
Merck to Pay $4.85 Billion To Settle Most Vioxx Cases
11/09/07 - AngelReyesBlog.com
In a very significant announcement today, Merck has released that it will agree to pay about $4.85 billion to settle a significant portion of the 27,000 cases against it's painkiller Vioxx. (read
more..)
Cephalon Drug Is Tied to Several Deaths
9/14/07 - The Wall Street Journal
Drug maker Cephalon Inc. sent letters to doctors this week warning them
that several deaths have been linked to Fentora, its powerful narcotic to
treat acute cancer pain. (read
more..)
$5.5 Million Award in First Federal Fentanyl (Duragesic) Pain Patch Trial
6/19/07 - Press Release
The family of a Florida man has won a $5.5 million wrongful death verdict
against two subsidiaries of pharmaceutical giant Johnson & Johnson in
the nation's first federal trial involving a patch form of the narcotic painkiller
fentanyl. (read
more...)
CONTACT FORM